Stay updated on SubQ Efgartigimod in CIDP Clinical Trial
Sign up to get notified when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.

Latest updates to the SubQ Efgartigimod in CIDP Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check19 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a Phase 2 study for efgartigimod in CIDP, while a new revision number has been added.SummaryDifference20%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check71 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.7%
Stay in the know with updates to SubQ Efgartigimod in CIDP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Efgartigimod in CIDP Clinical Trial page.